{"article_title": "Using ultrasound to treat stroke: Cerevast Therapeutics raises $10M", "article_keywords": ["therapeutics", "clotbust", "lost", "10m", "trial", "ultrasound", "stroke", "brain", "raises", "device", "using", "er", "companys", "cerevast", "treat"], "article_url": "http://medcitynews.com/2014/12/using-ultrasound-treat-stroke-cerevast-therapeutics-raises-10m/", "article_text": "They say that with a stroke, \u201ctime lost is brain lost\u201d \u2013 so when a stroke happens, each second counts to stave off further brain damage. Seattle-area startup Cerevast Therapeutics is developing a device that emits ultrasound waves meant to quickly dislodge stroke-causing blood clots in the brain.\n\nAnd company just raised $10 million, according to a regulatory filing.\n\nThe company\u2019s head-worn device, called the ClotBust ER, is made up of a number of ultrasound transducers that are placed in regions where the majority of vessel occlusions in the brain are known to occur, Cerevast says.\n\n\n\nThis fall, Cerevast announced the first interim results of its ongoing Phase 3 trial. This initial bit analyzed the 90-day functional recovery of 250 randomized patients.\n\nThe study\u2019s being conducted at 60 stroke centers in 14 countries.\n\nThe company\u2019s Clotbust ER trial is currently enrolling patrients.", "article_metadata": {"description": "They say that with a stroke, \u201ctime lost is brain lost\u201d \u2013 so when a stroke happens, each second counts to stave off further brain damage. Seattle-area startup Cerevast Therapeutics\u00a0is developing a device that emits ultrasound waves meant to quickly dislodge stroke-causing blood clots in the brain. And\u00a0company just raised $10 million, according to a regulatory filing. The company\u2019s head-worn device, called the ClotBust ER, is made up of a number of ultrasound transducers that are placed in regions where the majority of vessel occlusions in the brain are known to occur, Cerevast says. This fall, Cerevast announced the first interim results of its ongoing Phase 3 trial. This initial bit analyzed\u00a0the 90-day functional recovery of 250 randomized patients. The study\u2019s being conducted at 60 stroke centers in 14 countries. The company\u2019s Clotbust ER trial is currently enrolling patrients.", "generator": "WordPress 4.5.2", "og": {"site_name": "MedCity News", "description": "They say that with a stroke, \u201ctime lost is brain lost\u201d \u2013 so when a stroke happens, each second counts to stave off further brain damage. Seattle-area startup Cerevast Therapeutics\u00a0is developing a device that emits ultrasound waves meant to quickly dislodge stroke-causing blood clots in the brain. And\u00a0company just raised $10 million, according to a regulatory filing. The company\u2019s head-worn device, called the ClotBust ER, is made up of a number of ultrasound transducers that are placed in regions where the majority of vessel occlusions in the brain are known to occur, Cerevast says. This fall, Cerevast announced the first interim results of its ongoing Phase 3 trial. This initial bit analyzed\u00a0the 90-day functional recovery of 250 randomized patients. The study\u2019s being conducted at 60 stroke centers in 14 countries. The company\u2019s Clotbust ER trial is currently enrolling patrients.", "title": "Using ultrasound to treat stroke: Cerevast Therapeutics raises $10M", "locale": "en_US", "image": "http://medcitynews.com/wp-content/uploads/Screen-Shot-2014-08-14-at-2.41.29-AM.png", "updated_time": "2014-12-29T08:19:49-04:00", "url": "http://medcitynews.com/2014/12/using-ultrasound-treat-stroke-cerevast-therapeutics-raises-10m/", "type": "article"}, "twitter": {"image": "http://medcitynews.com/wp-content/uploads/Screen-Shot-2014-08-14-at-2.41.29-AM.png", "title": "Using ultrasound to treat stroke: Cerevast Therapeutics raises $10M - MedCity News", "description": "They say that with a stroke, \u201ctime lost is brain lost\u201d \u2013 so when a stroke happens, each second counts to stave off further brain damage. Seattle-area startup Cerevast Therapeutics\u00a0is developing a device that emits ultrasound waves meant to quickly dislodge stroke-causing blood clots in the brain. And\u00a0company just raised $10 million, according to a regulatory filing. The company\u2019s head-worn device, called the ClotBust ER, is made up of a number of ultrasound transducers that are placed in regions where the majority of vessel occlusions in the brain are known to occur, Cerevast says. This fall, Cerevast announced the first interim results of its ongoing Phase 3 trial. This initial bit analyzed\u00a0the 90-day functional recovery of 250 randomized patients. The study\u2019s being conducted at 60 stroke centers in 14 countries. The company\u2019s Clotbust ER trial is currently enrolling patrients.", "card": "summary", "creator": "@meghanakeshavan"}, "robots": "noodp", "fb": {"app_id": 148725768475669}, "article": {"section": "Daily", "tag": "Washington", "published_time": "2014-12-25T06:00:26-04:00", "modified_time": "2014-12-29T08:19:49-04:00"}, "keywords": "weight loss, obesity, overweight,diabetes,massachusetts,medical devices,obesity,startups,healthcare innovation, medcity news,medcity news,san francisco, startups, life sciences,accelerator,rock health,startup advice,startup funding,patient monitoring system, motion sensors ,dc,healthcare it,washington,foodborne pathogens, diagnostics company, diagnostic platforms,minimally invasive surgery, laser surgery,cambridge,dealflow,hospitals,wellpoint, healthways, health and wellness, employee wellness programs,investing,wellness,medtronic, shanghai innovation center, china, r&d,china,mdt,minneapolis,minnesota,publics,twin cities,ulcerative colitis, abbott labs, humira,abbott labs,doctors,pharmaceuticals,skin disorders, pharmaceuticals, md anderson cancer center,cancer,texas,renal denervation, st. jude medical,st. jude medical,stj,emr, ehr, electronic health records, electronic medical records, certified emr,certified emr,ehr,electronic health records,electronic medical records,advanced cellular technology,amyotrophic lateral sclerosis,embryonic stem cells,geron corporation,lou gehrig\\'s disease,macular degeneration,regenerative medicine,spinal cord damage,value-based healthcare system, obamacare, fee-for-service model,california,cleveland,health insurance,insurance,ohio,pennsylvania,politics,cancer treatment options library, aetna, aet, healthcare it,aet,aetna,health it,phi,philadelphia,ischemic stroke, Seattle, stroke, Washington, , MedCity News", "google-site-verification": "xudQg7nxVR9ifmMTY4Tf-0wVtX9b6rWLQd0utCweGOc", "viewport": "width=device-width,initial-scale=1.0,width=device-width,user-scalable=no,minimum-scale=1.0,maximum-scale=1.0"}, "_id": "\"57477af36914bd0286fcf151\"", "article_summary": "They say that with a stroke, \u201ctime lost is brain lost\u201d \u2013 so when a stroke happens, each second counts to stave off further brain damage.\nThe company\u2019s Clotbust ER trial is currently enrolling patrients.\nSeattle-area startup Cerevast Therapeutics is developing a device that emits ultrasound waves meant to quickly dislodge stroke-causing blood clots in the brain.\nThis fall, Cerevast announced the first interim results of its ongoing Phase 3 trial.\nThe company\u2019s head-worn device, called the ClotBust ER, is made up of a number of ultrasound transducers that are placed in regions where the majority of vessel occlusions in the brain are known to occur, Cerevast says."}